Observe Medical ASA - Registration of share capital increase
Oslo, 10 March 2022: Reference is made to the stock exchange announcement by Observe Medical ASA (the "Company") on 8 March 2022 regarding the Company's completion of the acquisition of Biim Ultrasound AS and the issuance of 8,171,913 new shares in the Company as partial consideration to the sellers of Biim Ultrasound AS (the "Consideration Shares").
The share capital increase pertaining to the Consideration Shares has now been registered with the Norwegian Register of Business Enterprises. The Company's new registered share capital is NOK 13,907,830.56, divided on 53,491,656 shares, each with a par value of NOK 0.26.
For further information about the Company, please contact:
Björn Larsson, CEO of Observe Medical,
Mobile: +46 76 620 17 25
E-mail: [email protected]
Per Arne Nygård, CFO of Observe Medical,
Mobile: +47 411 04 345
E-mail: [email protected]
About Observe Medical
Observe Medical develops and markets and sells innovative hospital products that contribute to increased patient safety and a more efficient care system. The Company's ambition is to drive growth by leveraging its expertise in sales and commercialization of its broad portfolio of medical technology products, mainly in the areas of Urine measurement, Anesthesiology/ICUs, surgery and wound care, in combination with targeted M&A. The Company is headquartered in Oslo, Norway and its operations are based out of Gothenburg, Sweden. Observe Medical has a direct sale organization in the Nordics and a distributor network internationally.
Further information is available at www.observemedical.com
About Sippi®
Sippi® is Observe Medical's first proprietary product and is the only automated digital urine meter with the possibility for wireless data transfer to the hospital patient data management systems and hinders bacterial migration that can lead to urinary infections (SippCoat®). Sippi® is CE marked and is currently being rolled out with a focus on selected markets and hospitals in Europe. Enhanced distribution and market access, gathering of clinical evidence and experience from pilot users is emphasized in this phase.
About Biim Ultrasound
Biim Ultrasound is headquartered in Norway with subsidiaries in Finland and the USA. The Company's vision is to develop high quality, affordable point-of-care ultrasound imaging available to a broad range of trained medical professionals. The Company is committed to improving patient care and reducing healthcare costs by enabling faster and easier diagnostic ultrasound imaging. The Company's device, Biim, is a handheld, wireless, app-based ultrasound which puts the power of fast, flexible, cordless ultrasound in your hands. With the ability to scan patients and review images in seconds, it offers a practical and affordable way to enhance decision-making and help improve patient outcomes.
Further information is available at www.biimultrasound.com
